

United States Patent and Trademark Office

AT

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| PPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|--|----------------|----------------------|------------------------|------------------|
| 10/009,792 | 12/13/2001 | San-Yup Lee | HYLEE60.001APC | 5798 |
| 20995 75 | 590 05/07/2004 | | EXAM | INER |
| KNOBBE MARTENS OLSON & BEAR LLP | | | DEVI, SARVAMANGALA J N | |
| 2040 MAIN STREET FOURTEENTH FLOOR IRVINE, CA 92614 | | | ART UNIT | PAPER NUMBER |
| | | | 1645 | J |

DATE MAILED: 05/07/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

| | Application No. | Applicant(s) | | | |
|--|---|---|--|--|--|
| Office Action Commence | 10/009,792 | LEE ET AL. | | | |
| Office Action Summary | Examiner | Art Unit | | | |
| | S. Devi, Ph.D. | 1645 | | | |
| The MAILING DATE of this communication app Period for Reply | ears on the cover sheet wit | h the correspondence address | | | |
| A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period we Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). | 66(a). In no event, however, may a re within the statutory minimum of thirty ill apply and will expire SIX (6) MONT cause the application to become ABA | ply be timely filed (30) days will be considered timely. THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133). | | | |
| Status | · | | | | |
| 1) Responsive to communication(s) filed on 3/29/ | <u>04</u> . | | | | |
| 2a) ☐ This action is FINAL . 2b) ☑ This | This action is FINAL . 2b)⊠ This action is non-final. | | | | |
| 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is | | | | | |
| closed in accordance with the practice under E | x parte Quayle, 1935 C.D. | 11, 453 O.G. 213. | | | |
| Disposition of Claims | • | • | | | |
| 4) ☐ Claim(s) 1-10 js/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1-10 are subject to restriction and/or expressions. | vn from consideration. | | | | |
| Application Papers | | • | | | |
| 9)☐ The specification is objected to by the Examine | r. | | | | |
| 10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner. | | | | | |
| Applicant may not request that any objection to the | | · ' | | | |
| Replacement drawing sheet(s) including the correcti 11) The oath or declaration is objected to by the Ex | · | • • | | | |
| Priority under 35 U.S.C. § 119 | | | | | |
| 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list of | s have been received. s have been received in Apity documents have been in (PCT Rule 17.2(a)). | pplication No received in this National Stage | | | |
| Attachment(s) | | | | | |
| 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) | , | ımmary (PTO-413) /Mail Date | | | |
| 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date | | ormal Patent Application (PTO-152) | | | |

Art Unit: 1645

Lack of Unity of Invention(s)

- 1) Claims 1-10 are under prosecution.
- Please Note: In an effort to enhance communication with our customers and reduce processing time, Group 1640 is running a Fax Response Pilot for Written Restriction Requirements. A Fax cover sheet is attached to this Office Action for your convenience. We encourage your participation in this Pilot program.
- 3) The instant inventions lack unity under PCT Rule 13.1 and 13.2:
 - I. Claims 1, 2 and 7-10, drawn to a recombinant plasmid vector comprising a nucleotide sequence encoding an oligopeptide having SEQ ID NO: 28 and a hG-CSF gene and a process of using the vector.
 - II. Claims 3-6, drawn to a recombinant plasmid vector comprising a modified nucleotide sequence which includes SEQ ID NO: 26 and a nucleotide sequence encoding an oligopeptide of SEQ ID NO: 1.

The special technical features of inventions I and II respectively are: a recombinant plasmid vector comprising a nucleotide sequence encoding an oligopeptide having SEQ ID NO: 28 and a hG-CSF gene; and a recombinant plasmid vector comprising a modified nucleotide sequence which includes SEQ ID NO: 26 and a nucleotide sequence encoding an oligopeptide of SEQ ID NO: 1. The products of inventions I and II lack significant common structural features. Consequently, the application lacks unity of invention.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to S. Devi, Ph.D., whose telephone number is (571) 272-0854. A telephone message may be left on the Examiner's voice mail system. The Examiner can normally be reached on Monday to Friday from 7.15 a.m. to 4.15 p.m. except one day each bi-week, which would be disclosed on the Examiner's voice mail system.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Lynette Smith, can be reached on (571) 272-0864.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

May, 2004

S. DEVI, PH.D.